Lately, we don't have to look far for doomsday news or potential policies that make us feel like a dystopian future will soon ...

Executive Director Winnie Byanyima said HIV infections have been falling in recent years, with just 1.3 million new cases ...

The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Writer-director Huo Meng’s Berlin competition entry follows an extended family of farmers scraping by as their country ...

What the Bible and history tell us about the claim that God gave the land of Israel to Abraham and his descendants.

Pres. Trump's proposal for the U.S. to take over Gaza is being denounced by the directors of 'No Other Land,' the ...

With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...